The stock price of Enovis Corp (NYSE: ENOV) has surged by 0.03 when compared to previous closing price of 34.59, but the company has seen a -1.48% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-17 that Wilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) — Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the “Investors” section of Enovis’ website at www.enovis.com.
Is It Worth Investing in Enovis Corp (NYSE: ENOV) Right Now?
Company’s 36-month beta value is 1.59.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ENOV is 56.11M, and currently, short sellers hold a 10.49% ratio of that floaft. The average trading volume of ENOV on May 02, 2025 was 903.17K shares.
ENOV’s Market Performance
The stock of Enovis Corp (ENOV) has seen a -1.48% decrease in the past week, with a -6.94% drop in the past month, and a -27.17% fall in the past quarter. The volatility ratio for the week is 3.07%, and the volatility levels for the past 30 days are at 5.96% for ENOV. The simple moving average for the past 20 days is 4.48% for ENOV’s stock, with a -18.57% simple moving average for the past 200 days.
Analysts’ Opinion of ENOV
Many brokerage firms have already submitted their reports for ENOV stocks, with JMP Securities repeating the rating for ENOV by listing it as a “Mkt Outperform.” The predicted price for ENOV in the upcoming period, according to JMP Securities is $62 based on the research report published on October 03, 2024 of the previous year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see ENOV reach a price target of $53. The rating they have provided for ENOV stocks is “Neutral” according to the report published on June 13th, 2024.
Stephens gave a rating of “Overweight” to ENOV, setting the target price at $72 in the report published on February 13th of the previous year.
ENOV Trading at -5.13% from the 50-Day Moving Average
After a stumble in the market that brought ENOV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.69% of loss for the given period.
Volatility was left at 5.96%, however, over the last 30 days, the volatility rate increased by 3.07%, as shares sank -6.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.32% lower at present.
During the last 5 trading sessions, ENOV fell by -1.48%, which changed the moving average for the period of 200-days by -22.66% in comparison to the 20-day moving average, which settled at $33.12. In addition, Enovis Corp saw -21.15% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ENOV
Current profitability levels for the company are sitting at:
- -0.36 for the present operating margin
- 0.52 for the gross margin
The net margin for Enovis Corp stands at -0.39. The total capital return value is set at -0.18. Equity return is now at value -27.69, with -17.95 for asset returns.
Based on Enovis Corp (ENOV), the company’s capital structure generated 0.35 points at debt to capital in total, while cash flow to debt ratio is standing at 0.08. The debt to equity ratio resting at 0.55. The interest coverage ratio of the stock is -13.11.
Currently, EBITDA for the company is -481.03 million with net debt to EBITDA at -2.66. When we switch over and look at the enterprise to sales, we see a ratio of 1.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.17.
Conclusion
In a nutshell, Enovis Corp (ENOV) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
